Vaxcyte, Inc.
PCVX
$59.70
-$0.66-1.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.06B | -946.53M | -766.63M | -657.20M | -547.50M |
| Total Depreciation and Amortization | 26.78M | 25.84M | 24.86M | 19.85M | 19.14M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 146.12M | 107.61M | 89.64M | 81.44M | 57.90M |
| Change in Net Operating Assets | 10.14M | 43.15M | -3.45M | 13.77M | 10.91M |
| Cash from Operations | -881.23M | -769.93M | -655.58M | -542.15M | -459.55M |
| Capital Expenditure | -39.84M | -45.02M | -56.97M | -78.58M | -104.61M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 190.44M | 125.64M | 494.33M | -156.36M | -1.17B |
| Cash from Investing | 150.60M | 80.63M | 437.35M | -234.94M | -1.27B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 622.36M | 617.83M | 13.01M | 15.58M | 1.54B |
| Repurchase of Common Stock | -16.34M | -15.00M | -10.99M | -11.07M | -16.43M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 606.02M | 602.84M | 2.01M | 4.51M | 1.52B |
| Foreign Exchange rate Adjustments | 1.20M | 603.00K | 2.44M | 3.61M | -2.25M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.41M | -85.86M | -213.77M | -768.96M | -211.71M |